Daridoreksant: interakcje

Prevention or Management: Avoid alcohol consumption with QUVIVIQ [see Warnings and Precautions (5.1) ] . (etykieta leku Daridoreksant, Interakcje z innymi lekami)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (etykieta leku Alprazolam, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (etykieta leku Azelastyna + flutykazon, Ostrzeżenia i środki ostrożności)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Buprenorfina, Ostrzeżenie w ramce)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina + kodeina, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Butalbital + paracetamol + kofeina + kodeina, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Butorfanol, Ostrzeżenie w ramce)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (etykieta leku Cetyryzyna, Ostrzeżenia i środki ostrożności)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Chlordiazepoksyd, Ostrzeżenia)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Chlordiazepoksyd + klidynium, Ostrzeżenia)

…have a breathing problem such as emphysema or chronic bronchitis glaucoma trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers When using this product excitability may occur, especially in children drowsiness may occur avoid alcoholic beverages alchohol, sedatives and tranquilizers… (etykieta leku Chlorfenamina, Ostrzeżenia)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (etykieta leku Chlorpromazyna, Przeciwwskazania)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (etykieta leku Cyklobenzapryna, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (etykieta leku Cyprofloksacyna, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Diazepam, Ostrzeżenia)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (etykieta leku Difenoksylat + atropina, Przeciwwskazania)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

…breathing problem such as emphysema or chronic bronchitis • glaucoma • trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking • a sedative or any other sleep-aid • tranquilizers • any other antihistamines • any other drugs When using this product • avoid alcoholic beverages • do not drive a motor vehicle or operate… (etykieta leku Doksylamina, Ostrzeżenia)

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (etykieta leku Doksylamina + pirydoksyna, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (etykieta leku Eszopiklon, Ostrzeżenia i środki ostrożności)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (etykieta leku Fenelzyna, Przeciwwskazania)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Fentanyl, Ostrzeżenie w ramce)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

CONTRAINDICATIONS Phenothiazines are contraindicated in patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. (etykieta leku Flufenazyna, Przeciwwskazania)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (etykieta leku Gabapentyna, Ostrzeżenia i środki ostrożności)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Hydrokodon, Ostrzeżenie w ramce)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (etykieta leku Hydrokodon + chlorfenamina, Ostrzeżenie w ramce)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (etykieta leku Hydrokodon + homatropina, Ostrzeżenie w ramce)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (etykieta leku Hydrokodon + ibuprofen, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Hydrokodon + paracetamol, Ostrzeżenie w ramce)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (etykieta leku Hydroksyzyna, Środki ostrożności)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (etykieta leku Hydromorfon, Ostrzeżenie w ramce)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (etykieta leku Karbinoksamina, Ostrzeżenia i środki ostrożności)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (etykieta leku Ketamina, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Klonazepam, Ostrzeżenia)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (etykieta leku Klonidyna, Ostrzeżenia i środki ostrożności)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Klorazepan, Ostrzeżenia)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Kodeina, Ostrzeżenie w ramce)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (etykieta leku Lewocetyryzyna, Ostrzeżenia i środki ostrożności)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Leworfanol, Ostrzeżenie w ramce)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (etykieta leku Lorazepam, Ostrzeżenia i środki ostrożności)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (etykieta leku Metadon, Ostrzeżenie w ramce)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (etykieta leku Metaksalon, Ostrzeżenia i środki ostrożności)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (etykieta leku Midazolam, Ostrzeżenie w ramce)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Morfina, Ostrzeżenie w ramce)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Nalbufina, Ostrzeżenie w ramce)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (etykieta leku Nalmefen, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Oksazepam, Ostrzeżenia)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (etykieta leku Oksybat sodu, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Oksykodon, Ostrzeżenie w ramce)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etykieta leku Oksykodon + paracetamol, Ostrzeżenie w ramce)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Oksymorfon, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Olicerydyna, Ostrzeżenie w ramce)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (etykieta leku Olopatadyna, Ostrzeżenia i środki ostrożności)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (etykieta leku Olopatadyna + mometazon, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Paracetamol + kodeina, Ostrzeżenie w ramce)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etykieta leku Pentazocyna + nalokson, Ostrzeżenie w ramce)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

CONTRAINDICATIONS Perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown… (etykieta leku Perfenazyna, Przeciwwskazania)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Petydyna, Ostrzeżenie w ramce)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etykieta leku Pokrzyk wilcza jagoda (belladonna) + opium, Ostrzeżenie w ramce)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (etykieta leku Pregabalina, Ostrzeżenia i środki ostrożności)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). Do not use in pediatric surgery. (etykieta leku Prochlorperazyna, Przeciwwskazania)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (etykieta leku Prometazyna + kodeina, Ostrzeżenie w ramce)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Remifentanyl, Ostrzeżenie w ramce)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Tapentadol, Ostrzeżenie w ramce)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Tramadol, Ostrzeżenie w ramce)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Tramadol + paracetamol, Ostrzeżenie w ramce)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (etykieta leku Triazolam, Ostrzeżenia i środki ostrożności)

CONTRAINDICATIONS A known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and preexisting liver damage. (etykieta leku Trifluoperazyna, Przeciwwskazania)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

Strong CYP3A4 inhibitors: Avoid concomitant use. (etykieta leku Daridoreksant, Interakcje z innymi lekami)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (etykieta leku Zaleplon, Ostrzeżenia)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (etykieta leku Zolpidem, Ostrzeżenia i środki ostrożności)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (etykieta leku Allopurynol, Ostrzeżenia i środki ostrożności)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (etykieta leku Aminofilina, Interakcje z innymi lekami)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (etykieta leku Biktegrawir + emtrycytabina + alafenamid tenofowiru, Interakcje z innymi lekami)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Use with CNS depressants may result in an additive or potentiating effect. (etykieta leku Brymonidyna, Interakcje z innymi lekami)

Use with CNS depressants may result in an additive or potentiating effect. (etykieta leku Brymonidyna + tymolol, Interakcje z innymi lekami)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Bupiwakaina, Ostrzeżenia i środki ostrożności)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Bupiwakaina + adrenalina, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (etykieta leku Buspiron, Interakcje z innymi lekami)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (etykieta leku Deutetrabenazyna, Interakcje z innymi lekami)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Lidokaina + adrenalina, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (etykieta leku Metyrozyna, Interakcje z innymi lekami)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (etykieta leku Nalokson, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (etykieta leku Teofilina, Interakcje z innymi lekami)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (etykieta leku Triheksyfenidyl, Interakcje z innymi lekami)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (etykieta leku Trimetobenzamid, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Risk increases when used with other central nervous system (CNS) depressants. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (etykieta leku Deksamfetamina, Interakcje z innymi lekami)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (etykieta leku Doksapram, Ostrzeżenia)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etykieta leku Epoetyna alfa, Ostrzeżenia i środki ostrożności)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (etykieta leku Prazosyna, Interakcje z innymi lekami)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (etykieta leku Montelukast, Interakcje z innymi lekami)